Thorium-227-based radioimmunotherapy tested in preclinical studies for the treatment of glioblastoma

Oct. 21, 2022

Investigators have developed α-therapeutic thorium-227-labeled DUNP19 ([227Th]Th-DUNP19), an antibody-conjugated radiopharmaceutical with high specificity and affinity to LRRC15.

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...

IMV-101 shows promise for B-cell malignancies

BioWorld Science

IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...